Please use this identifier to cite or link to this item:
Scopus Web of Science® Altmetric
Type: Journal article
Title: Cost savings with a new screening algorithm for pulmonary arterial hypertension in systemic sclerosis
Author: Quinlivan, A.
Thakkar, V.
Stevens, W.
Morrisroe, K.
Prior, D.
Rabusa, C.
Youssef, P.
Gabbay, E.
Roddy, J.
Walker, J.
Zochling, J.
Sahhar, J.
Nash, P.
Lester, S.
Rischmueller, M.
Proudman, S.
Nikpour, M.
Citation: Internal Medicine Journal, 2015; 45(11):1134-1140
Publisher: Wiley
Issue Date: 2015
ISSN: 1445-5994
Statement of
A. Quinlivan, V. Thakkar, W. Stevens, K. Morrisroe, D. Prior, C. Rabusa, P. Youssef, E. Gabbay, J. Roddy, J.G. Walker, J. Zochling, J. Sahhar, P. Nash, S. Lester, M. Rischmueller, S.M. Proudman, and M. Nikpour
Abstract: Background: Screening for pulmonary arterial hypertension (PAH) in systemic sclerosis (SSc) is now standard care in this disease. The existing Australian Scleroderma Interest Group algorithm (ASIGSTANDARD) is based on transthoracic echocardiography (TTE) and pulmonary function tests (PFT). Recently, ASIG has derived and validated a new screening algorithm (ASIGPROPOSED) that incorporates N-terminal pro-B-type natriuretic peptide level together with PFT in order to decrease reliance on TTE, which has some limitations. Right heart catheterisation (RHC) remains the gold standard for the diagnosis of PAH in patients who screen ‘positive’. Aim: To compare the cost of PAH screening in SSc with ASIGSTANDARD and ASIGPROPOSED algorithms. Methods: We applied both ASIGSTANDARD and ASIGPROPOSED algorithms to 643 screen-naïve SSc patients from the Australian Scleroderma Cohort Study (ASCS), assuming a PAH prevalence of 10%. We compared the costs of screening, the number of TTE required and both the total number of RHC required and the number of RHC needed to diagnose one case of PAH, and costs, according to each algorithm. We then extrapolated the costs to the estimated total Australian SSc population. Results: In screen-naïve patients from the ASCS, ASIGPROPOSED resulted in 64% fewer TTE and 10% fewer RHC compared with ASIGSTANDARD, with $1936 (15%) saved for each case of PAH diagnosed. When the costs were extrapolated to the entire Australian SSc population, there was an estimated screening cost saving of $946 000 per annum with ASIGPROPOSED, with a cost saving of $851 400 in each subsequent year of screening. Conclusions: ASIGPROPOSED substantially reduces the number of TTE and RHC required and results in substantial cost savings in SSc-PAH screening compared with ASIGSTANDARD.
Keywords: Scleroderma; pulmonary arterial hypertension; screening; algorithm; cost
Rights: © 2015 Royal Australasian College of Physicians
DOI: 10.1111/imj.12890
Grant ID:
Appears in Collections:Aurora harvest 3
Medicine publications

Files in This Item:
There are no files associated with this item.

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.